Can an old drug make immunotherapy work again for tough lymphomas?
NCT ID NCT05162976
First seen Jun 07, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This early-phase study tests whether adding an oral drug called CC-486 (azacitidine) to the immunotherapy nivolumab can help people with Hodgkin lymphoma whose cancer no longer responds to PD-1 blockers. About 33 participants will receive the combination to find the safest dose and see if tumors shrink. The hope is that CC-486 can 're-sensitize' the cancer to nivolumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral azacitidine (CC-486) plus nivolumab
What this could lead to
If it works, this combination could help patients whose Hodgkin lymphoma has stopped responding to standard immunotherapy, potentially making the cancer shrink or disappear again.
What could go wrong
This is a very early (Phase 1) trial with only 33 people, so it is not yet clear if the combination is safe or effective. Side effects from the drugs could be serious, and the benefit may be limited or absent.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.